| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
This compound does not have a defined biological target as it is primarily a chemical intermediate for drug synthesis. Its significance lies in its role as a building block for creating more complex molecules. As an aniline derivative, it can potentially be used in the synthesis of compounds that interact with a wide variety of receptors and enzymes, but the parent compound has no direct pharmaceutical activity.
|
|---|---|
| ln Vitro |
The compound itself is not a biologically active molecule; its value is purely as a synthetic precursor. It can be reacted with other molecules such as 2‑amino‑4‑methoxyphenol and 2‑amino‑4‑fluorophenol in research focused on pharmaceutical development, particularly in the development of anti‑cancer drugs, enhancing therapeutic efficacy.
|
| ln Vivo |
As a chemical intermediate and building block, 2-Amino-5-fluorophenol is not administered in vivo for research purposes. It is used as a starting material or intermediate in the chemical synthesis of other compounds that have biological activity and may be evaluated in vivo. The compound itself is not a drug candidate.
|
| Enzyme Assay |
Non-cell-based experiments for this compound are primarily analytical. A standard protocol for purity analysis uses GC with a flame ionization detector (FID). The purity is typically >97.0% (GC). For HPLC, a C18 reverse‑phase column with a mobile phase of acetonitrile and 0.1% TFA in water (gradient elution) and UV detection at 254 nm can be used. LC‑MS in positive ESI mode shows an [M+H]+ ion at m/z 128.1 (expected). The compound can also be analyzed by ¹H and ¹3C NMR to confirm structure.
|
| Cell Assay |
Cell-based experiments are not applicable for this intermediate, as it is a chemical building block and not a pharmacologically active compound. It is not intended for direct use in cell culture. Any biological activity or cell-based evaluation would be performed on the final drug substances synthesized using this building block, not on the intermediate itself.
|
| Animal Protocol |
In vivo animal experiments are not conducted for this compound. It is not a drug candidate and is not administered to animals for therapeutic evaluation. It is used as a chemical intermediate for the synthesis of active drug candidates that may eventually be tested in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable for this intermediate. Based on its physicochemical properties (molecular weight 127.12, log P ~1.3, TPSA 46.3 Angstrom2), the compound is moderately polar. It is a solid at room temperature (melting point not reported) and appears as a white to gray to brown powder or crystal. It is soluble in organic solvents such as DMSO and ethanol. The compound should be stored in a sealed, dry container at 2-8degC (refrigerated) or at room temperature, protected from light.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2-Amino-5-fluorophenol has not been fully characterized. As a research chemical, standard safety precautions apply. The compound may be harmful if swallowed, inhaled, or absorbed through the skin. It may cause skin and eye irritation. It should be handled in a well-ventilated area (fume hood) with appropriate PPE (lab coat, gloves, safety goggles). The GHS hazard class pictogram is Irritant, and the GHS signal word is Warning.
|
| References | |
| Additional Infomation |
Additional information: The compound has an MDL number of MFCD00671759. It is also known as 4‑Fluoro‑2‑hydroxyaniline. The product is for research and synthesis use only, not for human or veterinary use. It is available from chemical suppliers (e.g., TCI America, Bidepharm) with a purity of ≥97% (GC). Synonyms include 2-Amino-5-fluorophenol, 4-Fluoro-2-hydroxyaniline, and 2-Amino-5-fluorophenol.
|
| Molecular Formula |
C6H6FNO
|
|---|---|
| Molecular Weight |
127.12
|
| Exact Mass |
127.043
|
| CAS # |
53981-24-1
|
| PubChem CID |
185763
|
| Appearance |
Light brown to gray solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
99.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1F)O)N
|
| InChi Key |
IIDUNAVOCYMUFB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6FNO/c7-4-1-2-5(8)6(9)3-4/h1-3,9H,8H2
|
| Chemical Name |
2-amino-5-fluorophenol
|
| Synonyms |
4-Fluoro-2-hydroxyaniline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.8666 mL | 39.3329 mL | 78.6658 mL | |
| 5 mM | 1.5733 mL | 7.8666 mL | 15.7332 mL | |
| 10 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
